Market Overview

UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Bio-Rad Laboratories on 4Q12 Non-GAAP EPS

Related BIO
5 Health Care Stocks Hurting From The Affordable Care Act
UPDATE: Bio-Rad Labs Announces Resolution of Foreign Corrupt Practices Act

In a report published Wednesday, Jefferies reiterated its Buy rating on Bio-Rad Laboratories (NYSE: BIO), and raised its price target from $124.00 to $140.00.

Jefferies noted, “Excluding the benefit of a discrete gain (+$0.08), BIO's 4Q12 non-GAAP EPS of $1.57 was $0.23 (+17%) above consensus on a vastly better core revenue growth experience. We are raising our 2013 EPS forecast to $5.80 (from $5.75). Our price target moves to $140 (from $124) on higher cash flow forecasts.”

Bio-Rad Laboratories closed on Tuesday at $117.30.

Latest Ratings for BIO

DateFirmActionFromTo
Feb 2013JefferiesMaintainsBuy
Jan 2013CLSAUpgradesUnderperformOutperform
May 2012Jefferies & CompanyMaintainsBuy

View More Analyst Ratings for BIO
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (BIO)

Around the Web, We're Loving...

Get Benzinga's Newsletters